Authors
Mattia D'agostino, David A Cairns, Juan José Lahuerta, Ruth Wester, Uta Bertsch, Anders Waage, Elena Zamagni, María-Victoria Mateos, Daniele Dall'Olio, Niels WCJ van de Donk, Graham Jackson, Serena Rocchi, Hans Salwender, Joan Bladé Creixenti, Bronno van der Holt, Gastone Castellani, Francesca Bonello, Andrea Capra, Elias K Mai, Jan Dürig, Francesca Gay, Sonja Zweegman, Michele Cavo, Martin F Kaiser, Hartmut Goldschmidt, Jesús María Hernández Rivas, Alessandra Larocca, Gordon Cook, Jesús F San-Miguel, Mario Boccadoro, Pieter Sonneveld
Publication date
2022/10/10
Journal
Journal of clinical oncology
Volume
40
Issue
29
Pages
3406-3418
Publisher
Wolters Kluwer Health
Description
PURPOSE
Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. Moreover, chromosome 1q gain/amplification (1q+) recently proved to be a poor prognostic factor. In this study, we revised the R-ISS by analyzing the additive value of each single risk feature, including 1q+.
PATIENTS AND METHODS
The European Myeloma Network, within the HARMONY project, collected individual data from 10,843 patients with NDMM enrolled in 16 clinical trials. An additive scoring system on the basis of top features predicting progression-free survival (PFS) and overall survival (OS) was developed and validated.
RESULTS
In the training set (N = 7,072), at a median follow-up of 75 months, ISS, del(17p), lactate dehydrogenase, t(4 …
Total citations
Scholar articles
M D'agostino, DA Cairns, JJ Lahuerta, R Wester… - Journal of clinical oncology, 2022